This phase III , double-blind , placebo-controlled , parallel-group study randomized 320 patients with moderate to severe pain ( 4 intensity on an 11 point numeric rating scale ) following total knee replacement arthroplasty to receive oral TA-ER ( every 12 hours ) or TA-IR ( every 6 hours ) over a period of 48 hours .